Cancer drug design targeted by COSMIC's new 3D system

Collaboration between Wellcome Trust Sanger Institute and Astex Pharmaceuticals brings together COSMIC (Catalogue of Somatic Mutations In Cancer) and wwPDB (worldwide Protein Data Bank) to visualise genomic and proteomic data on cancer mutations

Cancer drug design targeted by COSMIC's new 3D system

TP53 mutant hotspots around DNA.png
TP53 molecule around DNA, showing hotspots of mutation, as displayed by COSMIC-3D

COSMIC-3D, the most comprehensive system for exploring cancer mutations in three dimensions, is launched today by COSMIC, based at the Wellcome Trust Sanger Institute, in collaboration with Astex Pharmaceuticals, Cambridge, UK. With extensive colourful and helpful visualisations, the new resource can help identify and characterise drug targets as well as support the design of new therapeutics for cancer.

The new tool is set to change the way researchers interact with genomic mutations in order to identify new cancer drug targets.

Available at http://cancer.sanger.ac.uk/cosmic3d, COSMIC-3D provides interactive 3D visualisations of more than 8,000 human proteins displaying cancer mutations. It enables researchers to develop a clearer understanding of which mutations are implicated in cancer progression, and how these mutations impact molecular structure and function.

Significantly, COSMIC-3D displays known and predicted drug binding sites within the protein structure. This displays cancer mutations alongside binding sites with predictions of how likely a pocket is to be successful as a drug target, enhancing the exploration and identification of how mutations impact therapeutic targets.

COSMIC-3D has been designed to directly assist pharmaceutical development. The new resource utilises COSMIC - Catalogue of Somatic Mutations in Cancer, the world’s largest expert-curated human cancer mutation database - and also incorporates structural information from the Worldwide Protein Data Bank (wwPDB).

“Combining cancer genomics data from COSMIC with the human structural proteome provides valuable insights into how cancer mutations affect molecular functions and impact cancer progression. This will enable scientists to better tackle the challenges of developing cancer-specific therapeutics.”

Dr Marcel Verdonk, Senior Director at Astex Pharmaceuticals

“This is a hugely exciting addition to the COSMIC family, COSMIC-3D will allow researchers to explore cancer mutations in a completely new way, providing new perspective for precision medicine.”

Dr Simon Forbes, Head of COSMIC at the Wellcome Trust Sanger Institute

Notes to Editors
Selected Websites
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Trust Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Genome editing reveals role of gene important for human embryo development

CRISPR-Cas9 genome editing shows that the protein OCT4 is essential in very early days of human embryo development

Huge genetic diversity among Papuan New Guinean peoples revealed

Genetic diversity found to mirror linguistic and cultural diversity among Papuan New Guinean people

Immunotherapy treatment option for selected breast cancer patients, genetic study suggests

Opens up the possibility of another therapy option for approximately 1,000 breast cancer patients in the UK